PubMed
GHRP-2: a GH secretagogue for clinical use
Bowers, 1997
GH SecretagoguesResearch OnlyD
GHRP-2
Pralmorelin
GHRP-2 (pralmorelin) is a synthetic hexapeptide GH secretagogue with stronger GH-releasing potency than GHRP-6 but with less pronounced appetite stimulation. Used in clinical research for GH deficiency diagnosis and studied for body composition effects. It is approved in Japan as a diagnostic agent for GH deficiency (Pralmorelin KM) but not approved for therapeutic use in the US.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- D
- Experience
- 14
- Activity
- 85
Overall check-ins
Trackers & reports
Overview
About GHRP-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide GH secretagogue with stronger GH-releasing potency than GHRP-6 but with less pronounced appetite stimulation. Used in clinical research for GH deficiency diagnosis and studied for body composition effects. It is approved in Japan as a diagnostic agent for GH deficiency (Pralmorelin KM) but not approved for therapeutic use in the US.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Pralmorelin
- Self-reports
- 26
Community
What 26 users report
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 3% · Unfavorable overall 94%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
162
Sleep
10
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
157
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 100–400 mcg
100–200
60
200–400
102
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 180 days · Based on 24 repeat reporters
Research
Cited research (2)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
Tools
Explore more
Explore
More ways to learn about GHRP-2 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about GHRP-2?
This page summarizes 26 anonymized self-reports from PeptIQ users who track GHRP-2, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for GHRP-2?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for GHRP-2?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is GHRP-2 safe to use?
This wiki does not assess safety or recommend use. GHRP-2 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of GHRP-2?
This wiki summarizes observational community reports and linked citations for GHRP-2. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for GHRP-2 for study-level context — not medical advice.
What is the legal status of GHRP-2?
GHRP-2 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of GHRP-2?
Safety data quality for GHRP-2 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on GHRP-2?
This page links 2 indexed sources for GHRP-2. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.